Nanoparticle Formulation
Nanoparticle Formulation - Related Videos
06:47
Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique
0 Views •
Cited by 16 •
2011
This article describes a nanoprecipitation method to synthesize polymer-based nanoparticles using diblock co-polymers. We will discuss the synthesis of diblock co-polymers, the nanoprecipitation technique, and potential applications.
02:43
Formulating mRNA-Loaded Nanoparticles for Vaccination Purposes
0 Views •
2025
This video demonstrates a method for generating an mRNA vaccine candidate using polymeric nanoparticles. The cationic polymer interacts with negatively charged mRNA, forming polyplexes. The formation of polyplexes stabilizes the mRNA, making it a potential candidate for future mRNA vaccines in immunotherapeutic applications.
02:57
Gel-Clot Limulus Amoebocyte Lysate Assay: A Method for Bacterial Endotoxin Detection in Nanoparticle Formulations
0 Views •
2025
This video describes a gel-clot assay to determine the presence of bacterial endotoxins in nano-formulations using Limulus Amoebocyte Lysate derived from the blood cells of horseshoe crabs. The assay helps test for endotoxin contamination of pharmaceutical products, including nano-based formulations.
06:06
Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles
0 Views •
Cited by 5 •
2019
We have previously used a gold nanoparticle peptide hybrid to intravenously deliver a synthetic peptide, protein kinase C-delta inhibitor, which reduced ischemia-reperfusion-induced acute lung injury. Here we show the detailed protocol of the drug formulation. Other intracellular peptides can be formulated similarly.
09:41
Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
0 Views •
Cited by 18 •
2021
Lipid nanoparticles are developed using a microfluidic mixing platform approach for mRNA and DNA encapsulation.
FAQs
Material selection and processing conditions determine whether the active compound becomes entrapped or remains associated with the carrier, while also shaping particle size, surface chemistry, drug loading, and stability. These variables are interdependent: changing the formulation process can alter how much drug is incorporated and how the particles interact with biological fluids. Optimization therefore requires evaluating the full property profile, not one variable alone.
Particle size and surface chemistry shape how a formulation behaves in biological fluids and interacts with target cells. These properties can influence distribution, release, and the possibility of limiting off-target exposure. Measuring them as part of formulation development helps connect physical design choices with biological performance and supports rational comparison among candidate formulations.
By packaging an active compound within or alongside a nanoscale carrier, the formulation can address limitations such as poor solubility, inadequate protection, or difficult administration. Its design can also influence distribution and release, creating opportunities to improve delivery while reducing exposure away from intended sites. These benefits remain potential outcomes that require experimental characterization.
Development begins by selecting suitable materials and processing conditions for particle formation and drug entrapment or association. The resulting formulation is then examined for size distribution, surface properties, loading efficiency, stability, release behavior, and biocompatibility. This sequence links preparation choices to measurable performance and provides evidence for deciding whether a candidate merits further clinical investigation.
A useful evaluation includes particle-size distribution, surface properties, drug-loading efficiency, stability, release behavior, and biocompatibility. Together, these measurements show whether the formulation has incorporated the active compound, maintained its intended characteristics, and produced a controlled release profile. They also help determine whether its physical and biological performance supports continued development.
Clinical researchers may investigate these formulations when a medicine has limited solubility, requires protection, is difficult to administer, or would benefit from altered distribution or release. The approach can also be studied when reducing off-target exposure is an important goal. Researchers must compare these potential advantages with measured stability, loading, release, and biocompatibility outcomes.
Biocompatibility is one of the essential performance characteristics considered before a formulation can advance toward clinical translation. Evaluating it alongside size, surface properties, loading, stability, and release helps establish whether the carrier behaves appropriately in a biological setting. This integrated assessment connects laboratory formulation design with the requirements of clinical research and further development.